Clinical utility of checkpoint inhibitors against metastatic bladder cancer: overcoming challenges to find a way forward-Reference-Cited by-同舟云学术

Clinical utility of checkpoint inhibitors against metastatic bladder cancer: overcoming challenges to find a way forward

Published:2023-04-10 Issue:5 Volume:23 Page:407-418
ISSN:1471-2598
Container-title:Expert Opinion on Biological Therapy
language:en
Short-container-title:Expert Opinion on Biological Therapy

Author:

Bilé-Silva Andreia¹,Lopez-Beltran Antonio²,Blanca Ana³,Lopez-Rios Fernando⁴^ORCID,Gómez-Gómez Enrique³,Cimadamore Alessia⁵,Montironi Rodolfo⁶,Vau Nuno⁷,Cheng Liang⁸

Affiliation:

1. Urology Department, Egas Moniz Hospital, Centro Hospitalar de Lisboa Ocidental, Lisbon, Portugal

2. Department of Morphological Sciences, Unit of Pathology, Cordoba University Medical School, Cordoba, Spain

3. Urology Department, Reina Sofia University Hospital, Cordoba, Spain

4. Pathology Department, 12 de Octubre University Hospital, Universidad Complutense de Madrid. Research Institute 12 de Octubre University Hospital (i+12), Madrid, Spain

5. Institute of Pathological Anatomy, Department of Medical Area (DAME), University of Udine, Udine, Italy

6. Molecular Medicine and Cell Therapy Foundation, Polytechnic University of Marche, Ancona, Italy

7. Medical Oncology, Champalimaud Clinical Center, Lisbon, Portugal

8. Department of Pathology and Laboratory Medicine, Brown University Warren Alpert Medical School, Providence, RI, USA

Publisher

Informa UK Limited

Subject

Clinical Biochemistry,Drug Discovery,Pharmacology

Link

https://www.tandfonline.com/doi/pdf/10.1080/14712598.2023.2201371

Reference95 articles.

1. Cancer IAfRo. Bladder cancer. 2022 [cited 2023 Feb 20]. Available from: https://www.iarc.who.int/cancer-type/bladder-cancer/#:~:text=Bladder%20cancer%20is%20the%2010th,cancers%20to%20diagnose%20and%20treat.

2. Immune Checkpoint Inhibitors for the Treatment of Bladder Cancer

3. Immune Checkpoint Inhibitors in Urothelial Carcinoma: Recommendations for Practical Approaches to PD-L1 and Other Potential Predictive Biomarker Testing

4. Narrative review: update on immunotherapy and pathological features in patients with bladder cancer

5. Immunotherapy for urothelial cancer: from the diagnostic pathologist’s point of view

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Programmed Cell Death Ligand 1 (PD-L1) Immunohistochemical Expression in Advanced Urothelial Bladder Carcinoma: An Updated Review with Clinical and Pathological Implications;International Journal of Molecular Sciences;2024-06-19

2. Advances in diagnosis and treatment of bladder cancer;BMJ;2024-02-12

3. Predictive and prognostic biomarkers in urological tumours;Pathology;2023-12